In draft re­port, ICER says Amy­lyx's ALS drug would not be cost ef­fec­tive if priced sim­i­lar­ly to old­er treat­ment

Rough­ly 24 hours af­ter Cana­di­an reg­u­la­tors gave Amy­lyx Phar­ma­ceu­ti­cals the thumbs-up for its new ALS drug, ICER is out with a new analy­sis try­ing to de­ter­mine whether the drug would be cost ef­fec­tive. And the short an­swer is no — for now.

Though Amy­lyx has not dis­closed how much it in­tends to charge for the drug, brand­ed as Al­bri­oza, ICER pegged its es­ti­mat­ed cost to an old­er ALS med­i­cine, edar­avone. If Al­bri­oza costs $169,000 per year, as edar­avone cur­rent­ly does, the drug would not be cost ef­fec­tive to the US health­care sys­tem, and far from it, ICER says.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER